These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 24732812)
1. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries. Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812 [TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781 [TBL] [Abstract][Full Text] [Related]
3. Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer. Ha J; Kim MH; Jo K; Lim Y; Bae JS; Lee S; Kang MI; Cha BY; Lim DJ Medicine (Baltimore); 2017 Jul; 96(29):e7512. PubMed ID: 28723762 [TBL] [Abstract][Full Text] [Related]
4. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer. Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095 [TBL] [Abstract][Full Text] [Related]
5. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378 [TBL] [Abstract][Full Text] [Related]
6. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients. Rosario PW; Xavier AC; Calsolari MR Thyroid; 2010 Nov; 20(11):1247-52. PubMed ID: 20950256 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation. Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300 [TBL] [Abstract][Full Text] [Related]
8. Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod). Leenhardt L; Leboulleux S; Bournaud C; Zerdoud S; Schvartz C; Ciappuccini R; Kelly A; Morel O; Dygai-Cochet I; Rusu D; Chougnet CN; Lion G; Eberlé-Pouzeratte MC; Catargi B; Kabir-Ahmadi M; Le Peillet Feuillet E; Taïeb D J Clin Endocrinol Metab; 2019 Apr; 104(4):1020-1028. PubMed ID: 30398518 [TBL] [Abstract][Full Text] [Related]
9. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. Tala H; Robbins R; Fagin JA; Larson SM; Tuttle RM J Clin Endocrinol Metab; 2011 Jul; 96(7):2105-11. PubMed ID: 21565788 [TBL] [Abstract][Full Text] [Related]
10. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257 [TBL] [Abstract][Full Text] [Related]
11. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden. Ciappuccini R; Hardouin J; Heutte N; Vaur D; Quak E; Rame JP; Blanchard D; de Raucourt D; Bardet S Eur J Endocrinol; 2014 Aug; 171(2):247-52. PubMed ID: 24866576 [TBL] [Abstract][Full Text] [Related]
12. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b). Rosario PW; Mourão GF; Calsolari MR Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001 [TBL] [Abstract][Full Text] [Related]
13. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896 [TBL] [Abstract][Full Text] [Related]
14. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients. Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569 [TBL] [Abstract][Full Text] [Related]
15. Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal. Vallejo Casas JA; Mena Bares LM; Gálvez Moreno MA; Moreno Ortega E; Marlowe RJ; Maza Muret FR; Albalá González MD Q J Nucl Med Mol Imaging; 2016 Jun; 60(2):163-71. PubMed ID: 26563902 [TBL] [Abstract][Full Text] [Related]
16. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411 [TBL] [Abstract][Full Text] [Related]
17. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma. Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882 [TBL] [Abstract][Full Text] [Related]
18. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272 [TBL] [Abstract][Full Text] [Related]
19. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation. Vrachimis A; Schober O; Riemann B Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096 [TBL] [Abstract][Full Text] [Related]
20. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Schlumberger M; Leboulleux S; Catargi B; Deandreis D; Zerdoud S; Bardet S; Rusu D; Godbert Y; Buffet C; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Toubert ME; Kelly A; Benhamou E; Borget I Lancet Diabetes Endocrinol; 2018 Aug; 6(8):618-626. PubMed ID: 29807824 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]